Predictive factors for EGFR -tyrosine kinase inhibitor retreatment in patients with EGFR -mutated non-small-cell lung cancer – A multicenter retrospective SEQUENCE study

Lung Cancer ◽

10.1016/j.lungcan.2016.12.002 ◽

2017 ◽

Vol 104 ◽

pp. 58-64 ◽

Author(s):

Gee-Chen Chang ◽

Chien-Hua Tseng ◽

Kuo-Hsuan Hsu ◽

Chong-Jen Yu ◽

Cheng-Ta Yang ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Tyrosine Kinase Inhibitor ◽

Predictive Factors ◽

Kinase Inhibitor ◽

Small Cell Lung ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Mutated ◽

Download Full-text

Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in EGFR-Mutated Non–Small Cell Lung Cancer

Molecular Cancer Therapeutics ◽

10.1158/1535-7163.mct-17-1033 ◽

2018 ◽

Vol 17 (4) ◽

pp. 740-750 ◽

Author(s):

Toshiyuki Hirano ◽

Hiroyuki Yasuda ◽

Junko Hamamoto ◽

Shigenari Nukaga ◽

Keita Masuzawa ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Third Generation ◽

Small Cell Lung ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Mutated ◽

Structural Characterizations

Download Full-text

Impact of Continuing First-Line EGFR Tyrosine Kinase Inhibitor Therapy Beyond RECIST Disease Progression in Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer (NSCLC): Retrospective GFPC 04-13 Study

Targeted Oncology ◽

10.1007/s11523-015-0387-4 ◽

2015 ◽

Vol 11 (2) ◽

pp. 167-174 ◽

Author(s):

J. B. Auliac ◽

C. Fournier ◽

C. Audigier Valette ◽

M. Perol ◽

A. Bizieux ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Small Cell Lung ◽

Egfr Tyrosine Kinase Inhibitor ◽

Tyrosine Kinase Inhibitor Therapy ◽

Download Full-text

Egfr-Tyrosine Kinase Inhibitor (Tki) Rechallenge with Bevacizumab in Egfr-Mutant Non-Small Cell Lung Cancer (Nsclc)

Annals of Oncology ◽

10.1093/annonc/mdu349.65 ◽

2014 ◽

Vol 25 ◽

pp. iv452

Author(s):

K. Otsuka ◽

A. Hata ◽

R. Kato ◽

J. Takeshita ◽

C. Okuda ◽

...

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Tyrosine Kinase Inhibitor ◽

Cell Lung Cancer ◽

Kinase Inhibitor ◽

Small Cell Lung ◽

Egfr Tyrosine Kinase Inhibitor ◽

Download Full-text

Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis

10.1186/1471-2407-11-1 ◽

2011 ◽

Vol 11 (1) ◽

Author(s):

Satoshi Watanabe ◽

Junta Tanaka ◽

Takeshi Ota ◽

Rie Kondo ◽

Hiroshi Tanaka ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Tyrosine Kinase Inhibitor ◽

Cancer Patients ◽

Kinase Inhibitor ◽

Small Cell Lung ◽

Egfr Tyrosine Kinase Inhibitor ◽

Lung Cancer Patients ◽

Clinical Responses

Download Full-text

Calpain4 Regulates The Response Of Non-Small Cell Lung Cancer Cell Lines To EGFR Tyrosine Kinase Inhibitor Erlotinib

10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a6288 ◽

2012 ◽

Author(s):

Sucheta Kulkarni ◽

Leya Saju ◽

Carol F. Farver

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Lung Cancer Cell ◽

Small Cell Lung ◽

Egfr Tyrosine Kinase Inhibitor

Download Full-text

CLINICAL ANALYSIS OF AFATINIB IN EGFR-TYROSINE KINASE INHIBITOR NAÏVE PATIENTS WITH NON-SMALL CELL LUNG CANCER HABORING EGFR MUTATIONS

Respirology ◽

10.1111/resp.13207_77 ◽

2017 ◽

Vol 22 ◽

pp. 114-114 ◽

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Clinical Analysis ◽

Egfr Mutations ◽

Small Cell Lung ◽

Egfr Tyrosine Kinase Inhibitor

Download Full-text

Abstract 3802: Effect of CS-7017, a selective PPARδ agonist, on the TGFβ/Smad-mediated enhanced cell motility of EGFR-tyrosine kinase inhibitor-resistant non-small cell lung cancer cells

10.1158/1538-7445.am2012-3802 ◽

2012 ◽

Author(s):

Masakuni Serizawa ◽

Masaru Watanabe ◽

Junko Suzuki ◽

Akane Naruoka ◽

Haruyasu Murakami ◽

...

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Cell Motility ◽

Tyrosine Kinase Inhibitor ◽

Cancer Cells ◽

Kinase Inhibitor ◽

Small Cell Lung ◽

Egfr Tyrosine Kinase Inhibitor

Download Full-text

Evaluation of the potential effect of dacomitinib, an EGFR tyrosine kinase inhibitor, on ECG parameters in patients with advanced non-small cell lung cancer

Investigational New Drugs ◽

10.1007/s10637-019-00887-0 ◽

2019 ◽

Vol 38 (3) ◽

pp. 874-884

Author(s):

Weiwei Tan ◽

Nagdeep Giri ◽

Susan Quinn ◽

Keith Wilner ◽

Kourosh Parivar

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Tyrosine Kinase Inhibitor ◽

Cell Lung Cancer ◽

Kinase Inhibitor ◽

Potential Effect ◽

Small Cell Lung ◽

Egfr Tyrosine Kinase Inhibitor

Download Full-text

Spatiotemporal T790M heterogeneity in individual patients with non-small cell lung cancer (NSCLC) after acquired resistance to EGFR-tyrosine kinase inhibitor (TKI).

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.8067 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 8067-8067 ◽

Author(s):

Akito Hata ◽

Nobuyuki Katakami ◽

Hiroshige Yoshioka ◽

Katsuhiro Masago ◽

Shiro Fujita ◽

...

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Tyrosine Kinase Inhibitor ◽

Cell Lung Cancer ◽

Kinase Inhibitor ◽

Acquired Resistance ◽

Small Cell Lung ◽

Egfr Tyrosine Kinase Inhibitor

Download Full-text

A single-arm phase II study of afatinib treatment for advanced EGFR-mutant non-small cell lung cancer (mNSCLC) patients (pts) with EGFR-tyrosine kinase inhibitor (TKI) resistance.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.e19031 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. e19031-e19031 ◽

Author(s):

Jair Bar ◽

Dana Botser ◽

Rossie Navon ◽

Nir Peled ◽

Haim Biran ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Phase Ii Study ◽

Small Cell Lung ◽

Egfr Tyrosine Kinase Inhibitor ◽

Tki Resistance ◽

Download Full-text